{"id":510128,"date":"2021-07-07T07:04:01","date_gmt":"2021-07-07T11:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/"},"modified":"2021-07-07T07:04:01","modified_gmt":"2021-07-07T11:04:01","slug":"nevro-to-report-second-quarter-2021-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/","title":{"rendered":"Nevro to Report Second Quarter 2021 Financial Results"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Company to Host Conference Call on Wednesday, August 4, 2021, at 1:30 pm PT \/ 4:30 pm ET<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">REDWOOD CITY, Calif.<\/span>, <span class=\"xn-chron\">July 7, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0that the company will report its financial results for the second quarter ended <span class=\"xn-chron\">June 30, 2021<\/span> after the market closes on <span class=\"xn-chron\">August 4, 2021<\/span>.<\/p>\n<p>Management will host a conference call on <span class=\"xn-chron\">August 4, 2021<\/span> to discuss second quarter 2021 financial results. The call will begin at <span class=\"xn-chron\">1:30 pm PT<\/span>\/ <span class=\"xn-chron\">4:30 pm ET<\/span>.\u00a0 Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 5842689. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro&#8217;s website at\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3208845-1&amp;h=365312846&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2879534-1%26h%3D4227538825%26u%3Dhttp%253A%252F%252Fwww.nevro.com%252F%26a%3Dwww.nevro.com&amp;a=www.nevro.com\" rel=\"nofollow noopener\">www.nevro.com<\/a><\/u>.\u00a0 <\/p>\n<p>\n        <b>Internet Posting of Information<\/b>\n      <\/p>\n<p>Nevro routinely posts information that may be important to investors in the &#8220;Investor Relations&#8221; section of its website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3208845-1&amp;h=2094716603&amp;u=http%3A%2F%2Fwww.nevro.com%2F&amp;a=www.nevro.com\" rel=\"nofollow noopener\">www.nevro.com<\/a>.\u00a0 The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.<\/p>\n<p>\n        <b>About Nevro<\/b>\n      <\/p>\n<p>Headquartered in <span class=\"xn-location\">Redwood City, California<\/span>, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.\u00a0 Nevro&#8217;s proprietary\u00a010 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in \u226565% of patients across six peer-reviewed clinical studies.\u00a0 The Senza\u00ae\u202fSystem, Senza II\u2122 System, and the Senza\u00ae\u202fOmnia\u2122 System\u202fare the only SCS systems that deliver Nevro&#8217;s proprietary 10 kHz\u202fTherapy.\u00a0 <\/p>\n<p>SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.<\/p>\n<p>To learn more about Nevro, connect with us on\u202f<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3208845-1&amp;h=1878756933&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D3237026080%26u%3Dhttps%253A%252F%252Fwww.linkedin.com%252Fcompany%252Fnevro%252F%26a%3DLinkedIn&amp;a=LinkedIn\" rel=\"nofollow noopener\">LinkedIn<\/a><\/u>,\u202f<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3208845-1&amp;h=1727894727&amp;u=https%3A%2F%2Ftwitter.com%2FNevro_HFX&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a><\/u>,\u202f<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3208845-1&amp;h=361308053&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D233801870%26u%3Dhttps%253A%252F%252Fwww.facebook.com%252FHF10therapy%252F%26a%3DFacebook&amp;a=Facebook\" rel=\"nofollow noopener\">Facebook<\/a><\/u>\u202fand\u202f<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3208845-1&amp;h=447011656&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2957666-1%26h%3D464884540%26u%3Dhttps%253A%252F%252Fwww.instagram.com%252Fnevro_hf10%252F%26a%3DInstagram&amp;a=Instagram\" rel=\"nofollow noopener\">Instagram<\/a><\/u>.<\/p>\n<p>\n        <b>Investors and Media: <br \/><\/b><br \/>\n        <span class=\"xn-person\">Julie Dewey<\/span>, IRC <br \/>Nevro Corp. <br \/>Vice President, Investor Relations &amp; Corp Communications <br \/>650-433-3247\u00a0 |\u00a0 <u><a target=\"_blank\" href=\"mailto:julie.dewey@nevro.com\" rel=\"nofollow noopener\">julie.dewey@nevro.com<\/a><\/u><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder7514\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg\" title=\".\" alt=\".\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=SF23731&amp;sd=2021-07-07\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/nevro-to-report-second-quarter-2021-financial-results-301324215.html\">https:\/\/www.prnewswire.com\/news-releases\/nevro-to-report-second-quarter-2021-financial-results-301324215.html<\/a><\/p>\n<p>SOURCE  Nevro Corp.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=SF23731&amp;Transmission_Id=202107070700PR_NEWS_USPR_____SF23731&amp;DateId=20210707\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company to Host Conference Call on Wednesday, August 4, 2021, at 1:30 pm PT \/ 4:30 pm ET PR Newswire REDWOOD CITY, Calif., July 7, 2021 \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021. Management will host a conference call on August 4, 2021 to discuss second quarter 2021 financial results. The call will begin at 1:30 pm PT\/ 4:30 pm ET.\u00a0 Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nevro to Report Second Quarter 2021 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-510128","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nevro to Report Second Quarter 2021 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nevro to Report Second Quarter 2021 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to Host Conference Call on Wednesday, August 4, 2021, at 1:30 pm PT \/ 4:30 pm ET PR Newswire REDWOOD CITY, Calif., July 7, 2021 \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021. Management will host a conference call on August 4, 2021 to discuss second quarter 2021 financial results. The call will begin at 1:30 pm PT\/ 4:30 pm ET.\u00a0 Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) &hellip; Continue reading &quot;Nevro to Report Second Quarter 2021 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-07T11:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nevro to Report Second Quarter 2021 Financial Results\",\"datePublished\":\"2021-07-07T11:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/\"},\"wordCount\":393,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/\",\"name\":\"Nevro to Report Second Quarter 2021 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\",\"datePublished\":\"2021-07-07T11:04:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/466682\\\/Nevro_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nevro-to-report-second-quarter-2021-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nevro to Report Second Quarter 2021 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nevro to Report Second Quarter 2021 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Nevro to Report Second Quarter 2021 Financial Results - Market Newsdesk","og_description":"Company to Host Conference Call on Wednesday, August 4, 2021, at 1:30 pm PT \/ 4:30 pm ET PR Newswire REDWOOD CITY, Calif., July 7, 2021 \/PRNewswire\/ &#8212;\u00a0Nevro Corp.\u00a0(NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced\u00a0that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on August 4, 2021. Management will host a conference call on August 4, 2021 to discuss second quarter 2021 financial results. The call will begin at 1:30 pm PT\/ 4:30 pm ET.\u00a0 Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) &hellip; Continue reading \"Nevro to Report Second Quarter 2021 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-07T11:04:01+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nevro to Report Second Quarter 2021 Financial Results","datePublished":"2021-07-07T11:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/"},"wordCount":393,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/","name":"Nevro to Report Second Quarter 2021 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","datePublished":"2021-07-07T11:04:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/466682\/Nevro_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nevro-to-report-second-quarter-2021-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nevro to Report Second Quarter 2021 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=510128"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/510128\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=510128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=510128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=510128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}